Predict your next investment

HEALTHCARE | Biotechnology
bonetherapeutics.eu

See what CB Insights has to offer

Founded Year

2006

Stage

IPO | IPO

Total Raised

$31.91M

Date of IPO

2/5/2015

Market Cap

0.01B

About Bone Therapeutics

Bone Therapeutics is an international biotechnology company specialized in the treatment of osteoarticular diseases using cell therapy. With its cell technology platform, the company is developing cell products for the repair and regeneration of bone and joint tissues.

Bone Therapeutics Headquarter Location

rue Auguste Piccard, 37

Gosselies, 6041,

Belgium

+32 (0)71 12.10.00

Latest Bone Therapeutics News

06:30 ET Global Allogeneic Cell Therapy Manufacturing Market to Record An Exponential CAGR of 17% By 2030

Jan 20, 2022

News provided by Share this article Share this article NEW YORK, Jan. 20, 2022 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Global Allogeneic Cell Therapy Manufacturing Market Trends, Industry Competition Analysis, Revenue, and Forecast to 2030." According to the latest market research study, the global allogeneic cell therapy manufacturing market is valued at US$ 869.6 million, and it is expected to reach US$ 3424.1 million by 2030 with a CAGR of 17% during a forecast period. Request for Sample Pages: https://www.insightaceanalytic.com/request-sample/1194 Allogeneic cell therapy products are producing stimulating pre-clinical and clinical results. Allogeneic cell therapies are created using healthy cells from unrelated donors, and these therapies rely on a single source of cells to treat large group patients. It is a procedure in which patient receives healthy cells (stem cells) from a donor to replace their own damaged or destroyed cells. Multiple factors such as the rising burden of chronic diseases such as cancer, diabetes, and cardiovascular diseases, increasing government funding for stem cell therapies, growing elderly population, developing healthcare infrastructure, advancements in technologies, rising public, and awareness about the benefits of allogeneic cell therapies are anticipated to fuel the demand for allogeneic cell therapy manufacturing market during the forecast period. Many pharma companies are launching allogeneic cell therapies to treat patients with chronic diseases. For instance, in March 2021, Adicet Bio, Inc., a biotechnology company developing allogeneic gamma delta T cell therapies for cancer and other diseases, began its First-in-Human Phase I clinical trial evaluating ADI-001 for the treatment of B cell non-Hodgkin's lymphoma (NHL). ADI-001 is an investigational first-in-class allogeneic gamma delta T cell therapy that expresses a chimeric antigen receptor (CAR) targeting CD20, produced to potentially increase selective tumor targeting and aid adaptive and innate anti-tumor immune response, and improve persistence for strong activity in patients. Owing to the increasing demand for cost-effective and efficient cell & gene therapies, outsourcing contract research organizations (CROs) have expanded the bioassay services, thereby boosting market growth opportunities in the near future. Request for ToC/Proposal: https://www.insightaceanalytic.com/report/global-allogeneic-cell-therapy-manufacturing-market-/1194 However, the high developmental investments and the immune rejection issues may inhibit the growth of the global allogeneic cell therapy manufacturing market in the upcoming years. North America is projected to dominate this market over the forecast period (2019-2030), followed by Europe and Asia-Pacific, due to the growing R&D investments in cell therapy research, high prevalence of chronic diseases, and quick adoption of advanced technologies. Major market players operating in the allogeneic cell therapy manufacturing market include Lonza Group, KBI Biopharma, Inc., Waisman Biomanufacturing, Cell, and Gene Therapy Catapult, Thermo Fisher Scientific, Inc., Merck KGaA, Catalent Inc., Oxford Biomedica Plc, Fujifilm Cellular Dynamics, Inc.,  Wuxi Apptec, Charles River Laboratories International, Inc., The Discovery Labs LLC, ABL, Inc., BioCentriq, Commercializing Living Therapies, and Other Prominent Player among others. Some significant developments in the market: In January 2022, Mesoblast Limited (Australi), a global leader in allogeneic cellular medicines for inflammatory diseases, presented 36-month follow-up results from thecPhase 3 trial of its allogeneic cell therapy rexlemestrocel-L (MPC-06-ID) in patients with CLBP (chronic low back pain) associated with DDD (degenerative disc disease). This trial showed a durable reduction in back pain lasting at least three years from a single intra-discal injection of rexlemestrocel-L+hyaluronic acid (HA) carrier. In November 2021, BONE THERAPEUTICS (Belgium), the cell therapy company, and Link Health Pharma Co., Ltd signed a non-binding term sheet for the global rights for ALLOB, allogeneic bone cell therapy of Bone Therapeutics'. In September 2021, Adaptimmune Therapeutics (UK) partnered with Roche Group (Genentech), to develop and commercialize allogeneic cell therapy for the treatment of multiple cancer indications. Curious about this latest version of the market research report? Obtain Report Details @ https://www.insightaceanalytic.com/enquiry-before-buying/1194 Market Segments Induced pluripotent stem cells (iPSC) T-cells and Natural killer (NK) cells Human pluripotent stem cells (hPSCs) Mesenchymal stem cells (MSC) Tissue engineered product Preclinical Scale Operations North America U.S. Germany India Brazil GCC Countries

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Bone Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Bone Therapeutics is included in 2 Expert Collections, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharma Tech

15,532 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Bone Therapeutics Patents

Bone Therapeutics has filed 15 patents.

The 3 most popular patent topics include:

  • Stem cells
  • Transcription factors
  • Developmental biology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/19/2016

1/23/2018

Autoimmune diseases, Arthritis, Rheumatology, Indoles, Rare diseases

Grant

Application Date

9/19/2016

Grant Date

1/23/2018

Title

Related Topics

Autoimmune diseases, Arthritis, Rheumatology, Indoles, Rare diseases

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.